Article: Tips and Tricks for Leveraging Advanced Flow Cytometry
Tips and tricks for fully leveraging Advanced Flow Cytometry.
List view / Grid view
Tips and tricks for fully leveraging Advanced Flow Cytometry.
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
Researchers have engineered CAAR T cells to destroy harmful antibodies, improving NMDA receptor encephalitis treatment.
Researchers have developed a new bioreactor that can manufacture T cells faster than other technologies, which may advance immunotherapy.
An epitope on CD95 receptor causes tumour cells to self-destruct and may prolong benefits of CAR T-cell therapy for solid tumours.
Bacteria programmed to paint targets on solid tumours for T cells to see eliminates the need for specific antigens.
4 October 2023 | By Halo Labs
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
14 July 2023 | By BPS Bioscience
Watch this webinar to get an overview of the CAR-T workflow and learn about the latest CAR-T research enabling tools that can accelerate your discovery.
Dr John Maher discusses the challenges associated with developing chimeric antigen receptor (CAR) T-cell therapy for solid tumours.
Download your FREE ebook, featuring articles about cancer therapies, immune system breakthroughs, therapeutic genetic engineering, and advancements in gene editing.
A new Drug Target Review issue is now ready to download! This issue features articles on cell and gene therapy, imaging and screening.
US researchers usings a ‘SNAP’ receptor system can customise immunotherapies for targeted treatments of cancer and other diseases.
4 April 2023 | By GenScript ProBio
The application of Fab and VHH naïve library to expedite the antibody discovery against tumor-associated antigen for CAR-T, ADC and bispecific antibody.
US discovery opens the way to drugs that can prevent T cell therapies from losing their potency over time.
US scientists suggest that anti-angiogenesis drugs could improve the function and delivery of CAR-T cell therapy.